Information  X 
Enter a valid email address

Company Name matching 'F-star Therapeutics, Inc'

Date
Time Source
Company
Announcement
17 May 2021 1:00 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
10 May 2021 1:00 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021
07 May 2021 12:00 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common Stock
06 May 2021 9:50 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
19 Apr 2021 2:27 pm GNW   F-star Therapeutics, Inc. Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
10 Apr 2021 2:22 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
01 Apr 2021 1:00 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
29 Mar 2021 1:00 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
04 Mar 2021 1:00 pm GNW   F-star Therapeutics, Inc. F-star Therapeutics to Present at Upcoming Investor Conferences
20 Jan 2021 1:00 pm GNW   F-star Therapeutics, Inc. F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
06 Jan 2021 1:00 pm GNW   F-star Therapeutics, Inc F-star Therapeutics to Participate in Upcoming Conferences
04 Jan 2021 1:00 pm GNW   F-star Therapeutics, Inc F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t